Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Boston Therapeutics, Inc. | s105634_ex32-2.htm |
| EX-31.2 - EXHIBIT 31.2 - Boston Therapeutics, Inc. | s105634_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - Boston Therapeutics, Inc. | s105634_ex31-1.htm |
| EX-23.1 - EXHIBIT 23.1 - Boston Therapeutics, Inc. | s105634_ex23-1.htm |
| EX-10.24 - EXHIBIT 10.24 - Boston Therapeutics, Inc. | s105634_ex10-24.htm |
| 10-K - 10-K - Boston Therapeutics, Inc. | s105634_10k.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEYACT OF 2002
In connection with the Annual Report on Form 10-K of Boston Therapeutics, Inc. (the "Company") for the year ending December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Carl W. Rausch, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
(1) The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 28, 2017 | By: | /s/ Carl W. Rausch |
| Carl W. Rausch | ||
| Chief Executive Officer |
This certification accompanies each Report pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.
A signed original of this written statement required by §906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.